title: Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
abstract: Based on fair quality Level 3 evidence, Lu et al.(1) note that glatiramer acetate (GA) exposure was not associated with lower mean birthweight, lower mean gestational age, preterm birth (37 weeks), congenital anomaly, or spontaneous abortion. However, GA was given an indeterminate recommendation because further research is needed. The results are not compelling: 3 of the 4 existing human studies of GA were small case series.(1.)
authors.forename: James A
authors.initials: JA
authors.lastname: Charles
authors.forename: Helen
authors.initials: H
authors.lastname: Tremlett
authors.forename: Ellen
authors.initials: E
authors.lastname: Lu
authors.forename: Colleen
authors.initials: C
authors.lastname: Guimond
authors.forename: A Dessa
authors.initials: AD
authors.lastname: Sadovnick
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D011247:Pregnancy; D000068717:Glatiramer Acetate; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000453:epidemiology; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D011248:Pregnancy Complications / Q000188:drug therapy / Q000453:epidemiology; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced / Q000453:epidemiology; D000078202:Systematic Reviews as Topic
chemical_list: D000068717:Glatiramer Acetate; D010455:Peptides